RCE Investor Webinar Presentation Deck
Released
Released
Announcement PDF
0
RCE Webinar
ASX:RCE | FSE:R9Q
March 2026
Disclaimer
DISCLAIMER
This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does
not purport to contain all the information that a prospective investor may require in connection
with any
potential investment in the Company. You should not treat the contents of this presentation,
or any information provided in connection with it, as financial advice, financial product advice
or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or any
of its officers, advisers, agents or employees as to the accuracy, completeness or
reasonableness of the information, statements, opinions or matters (express or implied)
arising out of, contained in or derived from this presentation or provided in connection with it,
or any omission from this presentation, nor as to the attainability of any estimates, forecasts
or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own
independent inquiries into the matters contained in the presentation and make your own
independent decisions about the affairs, financial position or prospects of the Company. The
Company reserves the right to update, amend or supplement the information at any time in its
absolute discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and
employees accept any responsibility or liability to you or to any other person or entity arising
out of this presentation including pursuant to the general law (whether for negligence, under
statute or otherwise), or under the Australian Securities and Investments Commission Act
2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding
provision of any Australian state or territory legislation (or the law of any similar legislation in
any other jurisdiction), or similar provision under any applicable law. Any such responsibility or
liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an
offer to buy or sell securities. It does not include all available information and should not be
used in isolation as a basis to invest in the Company.
1
FUTURE MATTERS
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of
the Company.
Those intentions, expectations, future plans, strategy and prospects may or may not be achieved. They are
based on certain assumptions, which may not be met or on which views may differ and may be affected by
known and unknown risks. The performance and operations of the Company may be influenced by a number of
factors, many of which are outside the control of the Company. No representation or warranty, express or
implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any
intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will
be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or
achievements to be materially different from those expected, planned or intended, recipients should not place
undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not
warrant or represent that the actual results, performance or achievements will be as expected, planned or
intended.
US DISCLOSURE
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any
securities in the United States or to, or for the account or benefit of any “US person” as defined in Regulation S
under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been, and will not be,
registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States,
and may not be offered or sold in the United States or to any US person without being so registered or
pursuant to an exemption from registration including an exemption for qualified institutional buyers.
Company
Overview
Introduction
James Graham
Chief Executive Officer
Recce Pharmaceuticals – Company Overview
• Publicly-traded on the Australian and Frankfurt exchanges – (ASX: RCE, FSE: R9Q).
• Therapeutics to address the global healthcare crisis of antibiotic resistance: works
faster than traditional antibiotics and against multidrug-resistant bacteria.
• Phase 3 Clinical trial (Indonesia) – patient dosing commenced.
• Multiple successful Phase I and Phase II clinical trials across Australia.
• US Defense Burn Research Program grant; US Army Medical Research Institute of
Infectious Diseases.
• >40 granted patents across major pharmaceutical markets out to 2041.
• Our goal is for our product to be made available in Indonesia in 2026.
An Australian clinical-stage biotech with a United States presence, developing a New Class of Synthetic Anti-infectives with a
unique mechanism of action for a broad spectrum of infections including serious/life-threatening indications.
RECCE® 327 granted Qualified Infectious Disease Product (QIDP)
Designation by U.S. Food and Drug Administration giving 10 years
market exclusivity plus fast-track approval.
RECCE® 327 added to World Health Organization’s List
of Antibacterial Products in Clinical Development.
3
Board and Management Structure
4
Dr John Prendergast – Chairman
BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)
US-based, current Chairman and Co-founder of Palatin Technologies, Inc.
(NYSE: PTN) and Lead Director of Nighthawk Biosciences (NYSE: HHWK). With
extensive experience in the international commercialisation of pharmaceutical
technologies, Dr Prendergast has been responsible for the approval of three
new drug applications, marking significant achievements in the pharmaceutical
landscape
James Graham – Managing Director & Chief Executive Officer
BCom (Entrepreneurship), GAICD
Mr Graham is the Chief Executive Officer of Recce Pharmaceuticals. He brings
extensive experience in marketing, business development, and the
commercialisation of early-stage technologies with global potential. With a
proven track record of growing globally focused companies, Mr Graham has
applied his expertise to Recce, including serving on its Board of Directors. He
has participated in nearly every capital raise to date, demonstrating a strong
commitment to expanding Recce’s commercial opportunities and clinical
programs.
Dr Alan Dunton – Chief Medical Advisor & Non-Executive Director
BSc (BioChem) Hons, M.D. (NYU)
US based, Director of Palatin Technologies. Over three decades of senior
pharmaceutical experience incl. President and MD of Janssen Research
Foundation (Johnson & Johnson). Dr Dunton has advanced a number of
blockbuster antibiotics through regulatory review and commercialisation at
Fortune 500 companies including Roche. Dr Dunton has been responsible for
the approval of approximately 20 New Drug Applications, fostering
advancements in numerous drug development and successful commercialisation
efforts.
Michele Dilizia – Executive Director & Chief Scientific Officer
BSc (Med Sci), Grad Dip Bus (Mkting), BA (Journ), GAICD, MASM
Co-inventor and qualified medical scientist with a specialisation in medical
microbiology and regulatory affairs. Ms Dilizia successfully co-led the
research and development of Recce’s suite of anti- infective
compounds, resulting in a portfolio of granted patents across the globe,
including a Qualified Infectious Disease Product designation with the U.S.
FDA.
Dr Justin Ward – Executive Director & Principal Quality Chemist
BSc (Chem), PhD (Chem), M Pharm, MRACI, CChem
A quality control expert who has worked with leading pharmaceutical
companies. He previously held a technical role with Pfizer, involving providing
data for the regulatory submissions to the FDA and TGA. Dr Ward is bringing
Recce’s research and development and manufacturing up to US FDA
requirements.
Alistair McKeough – Non-Executive Director
Mr McKeough is an experienced executive and solicitor. Before being
appointed as a non-executive director in 2022, Alistair served as Recce’s
company secretary and he has been involved with the company since 2017.
Alistair has extensive experience in a variety of private and listed corporations
across many sectors, including professional services, technology, financial
services, charities, health, biotech, childcare and education. Recent roles
include Managing Director of a legal practice specialising in equity capital
markets and advice to listed companies and as part of the senior leadership
team at share registry, Automic Group.
Elusys
Therapeutics
recce.com.au
The Advantages of a New Class of Antibiotics
Recce is on-track to be the only global clinical stage company whose drug is
shown to be efficacious against the full suite of ESKAPE pathogens
Universal Mechanism of Action - does not succumb to resistance
Unprecedented, broad-spectrum activity against Gram-positive and Gram-negative bacteria
Extremely rapid onset of effect – measured in minutes as compared to hours for typical antibiotics
Multiple formulations available – intravenous, topical liquid, topical gel and aerosol for inhalation or
intranasal
5
RECCE® 327
Clinical
Programs
6
Clinical Overview
Dr Alan W Dunton
Chief Medical Advisor & Non-Executive Director
recce.com.au 7
DFIs: Addressing a High-Burden Infection Setting
DFIs are complex infection
environments
• Compromised blood flow, impaired
immune response and high bacterial
burden
• Reduced penetration of systemic
antibiotics
• Delayed healing associated with
increased risk of escalation and
amputation
Local infection
management in DFIs
• Direct delivery of anti-infective
therapy to the site of infection
• Rapid bacterial kill without reliance
on systemic circulation
• Broad-spectrum activity suitable
for mixed bacterial populations
RECCE® 327 Gel was designed
with DFI complexity in mind
• Designed for direct application
within complex wound settings
• Designed to operate
independently of host circulation
• Broad-spectrum anti-infective
activity suitable for mixed and
unidentified bacterial populations
RECCE® 327 Topical Gel
First-Line Local Treatment for Infected Wounds
No Pathogen Identification Required
• Applied directly to infected tissue
• Localised antimicrobial action at the site of
infection
• Suitable for outpatient and community-based
care
Rapid Clinical Response
• Clinical and TGA Special Access Scheme
use demonstrates visible reduction in
infection, redness, and swelling within 24–
72 hours
• In vitro time-kill studies show fast
bactericidal activity within minutes
• Broad-spectrum activity against DFI and
wound pathogens, including resistant strains
• Eliminates delays associated with swabs,
cultures, and sensitivity testing
• Rapid onset of action, measured in hours not
days
Proven Antimicrobial Activity Safe and Well Tolerated
• Minimal systemic absorption
• Soothing clear gel
• Suitable for daily application
For illustrative purposes only – not final product
Topical Clinical Programs – Previously Completed
Phase I/II
Clinical Trial
Treatment of
Burn Wound
Infections
9
For illustrative purposes only – not final product
• Stage 1 Complete
• Patients treated with R327 showed good indications of safety
and tolerability
• No serious adverse events reported among patients
Phase I/II
Clinical Trial
Diabetic Foot
Infections (DFI)
• Interim data results released – primary endpoints achieved
• Patients supported by in-home (out-patient) nurses trained in
R327 treatment protocols
• Study across South Western Sydney health district – one of the
highest prevalence rates of diabetes in NSW
Phase II
Clinical Trial
ABSSSI
• This Phase II study achieved all primary and secondary
endpoints as an open-label clinical trial evaluating the safety
and tolerability, efficacy, and plasma pharmacokinetics of
R327G when applied directly to the infected area
recce.com.au
• This Phase II study achieved all primary and secondary endpoints as an open-label
clinical trial evaluating the safety and tolerability, efficacy, and plasma pharmacokinetics
of R327G when applied directly to the infected area
• The study enrolled 30 patients, with 29 included in the final data analysis. One patient
was withdrawn due to pre-existing pain at the wound site that was deemed unrelated to
R327G
• After 7 days of treatment, 86% of patients (25 out of 29) treated with R327G had a
successful clinical response
• At 14 days of treatment, 93% of patients (27 out of 29) achieved a primary efficacy
endpoint
• R327G demonstrated to be safe and well tolerated, achieving all endpoints - no Serious
Adverse Events reported
Phase II Acute Bacterial Skin and Skin Structure
Infections (ABSSSI) Clinical Trial
Achieved all Endpoints
Study Outcome* To evaluate the efficacy of RECCE®327 topical gel on ABSSSI
Assessment method Lipsky Scale/Bates Jensen Wound Assessment Tool
Endpoint met Yes
*https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=387997&isReview=true
Successful clinical response
86%
93%
After 7 days of treatment
After 14 days of treatment
10
Registrational Phase 3 Clinical Trial - Indonesia
11
Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Infections
Study Overview
Primary Endpoint: Assess the clinical response of the DFI according to the Lipsky Scale.
Secondary Endpoints: DFI total wound score and safety of R327G.
Endpoints
Multi-centre, 5 activated sites.
Multiple Clinical Trial Sites in Diverse Populations; Jakarta, Denpasar, Surabaya.
Locations
R327 Topical
Phase 3 Interim Data
Readout - 155 patients
Diabetic Foot Ulcer Infection GEL
INDONESIA/ASEAN
Indo trial data
used for global
registration strategy
R327G
Registered
in ASEAN
2026 2027
Timeline
R327G
Registered
in Indonesia
12
Etana & Recce
Program
Overview
Nathan Tirtana
Chief Executive Officer – Etana Biotechnologies
PT Etana Biotechnologies – Company Overview
Innovative, affordable biopharmaceuticals for Indonesia— in collaboration with Recce Pharmaceuticals
1
• Founded in 2014 – emerging producer of innovative, affordable
biopharmaceuticals.
• Focus areas: Infectious disease & other life-threatening diseases, cancer,
metabolic, autoimmune.
• Mission: expand access to life-saving medicines for all Indonesians.
• Global partnerships for R&D and drug development.
• Building Indonesia’s biotech capabilities with modern, eco-friendly
facilities.
• Collaborations with hospitals, doctors’ associations & government health
agencies.
• Commitment to long-term growth through product innovation & workforce
development.
Strategic Partnership in South-East Asia to Accelerate Clinical Program
• Recce and leading biomedical organisation PT Etana Biotechnologies
Memorandum of Understanding (MoU).
• MoU aims to facilitate late-stage clinical trials in Indonesia,
supporting the Indonesian Government’s access to novel
infectious disease medicines.
• Patient Population focussed upon significant unmet medical needs
particular to the region.
– Significant need for new therapeutics in Indonesia, with the
Government increasing its focus on addressing infectious diseases
and AMR.
• Historically, significant bilateral initiative supported by Australian
and Indonesian Government.
14
The purpose of the MoU is for both parties to work collaboratively on the research, development, production, distribution, and
commercialisation of a first-in-class therapeutic agent designed with broad spectrum anti-infective capabilities for potential
registrational use across Indonesia (and in other jurisdictions as otherwise agreed by the parties) to address the critical global
health challenge of antimicrobial-resistance.
Indonesian Minister of Health, Mr. Budi Sadikin
Registrational Phase 3 Clinical Trial - Indonesia
15
Study Title: Phase 3, Double-blind, Placebo-Controlled Study of R327 Topical Gel for the Treatment of Diabetic Foot Ulcer Infections
Multi-centre, 5 activated
sites across Indonesia.
Over 20.9 million adults in
Indonesia are living with
diabetes – more than 1 in
every 10 adults.
Up to 310 participants will
be enrolled who present with
a mild diabetic foot infection.
Interim data analysis to be
conducted after 155
participants.
Primary Endpoint: Assess the
clinical response of the DFI
according to the Lipsky Scale.
Secondary Endpoints: DFI total
wound score and safety of R327G.
Population
Locations Endpoints
Intervention
Participants to receive either R327
topical gel or placebo topical gel.
RECCE® 327
Topical Gel
16
Siloam Hospitals
Trial Site
Overview
Dr Jane Olivia Lorens
Clinical Research Department Head –
Siloam Clinical Research
Siloam Hospitals – Introduction
Industry Engagement in Indonesia
Regulatory Acceleration & ASEAN Commercial Entry
RECCE® 327
Clinical
Programs
20
Dept. of War
Burn Wound
Programs
David F. Lasseter
Founder and Partner of Horizons Global
Solutions
Ryan Kane
Founder and Managing Partner of RK
Strategies, Inc.
Speakers
David F. Lasseter is the Founder and Partner of Horizons Global Solutions, a consultancy specializing in national
security, law enforcement, intelligence and biotechnology.
He served as the Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction
(CWMD), supporting the Under Secretary of Defense for Policy and the Assistant Secretary of Defense for Global
Security. He oversaw the development and implementation of strategies and policies, the DoD Cooperative Threat
Reduction (CTR) Program, and Chemical, Biological, Radiological and Nuclear (CBRN) defence.
Prior to this he was the Deputy Assistant Attorney General for Legislative Affairs at the U.S. Department of Justice,
managing the national security portfolio. His early career includes serving on Capitol Hill as a Congressional Chief of
Staff, military legislative assistant, and counsel.
David holds an undergraduate degree from the University of Georgia, a Juris Doctor from the University of Alabama.
He is currently serving as an Officer in the United States Marine Forces Reserve and is also a Visiting Fellow at the
National Security Institute.
21
Ryan Kane is the Founder and Managing Partner of RK Strategies, Inc., a government and public affairs consultancy
specializing in healthcare, biodefense, preparedness, defense, and technology sectors. Founded in 2017, RK
Strategies advises publicly traded companies and organizations navigating complex U.S. government policy,
regulatory, and contracting environments.
He also serves as Vice President of Government Affairs at Elusys Therapeutics, where he oversees global
government affairs strategy for the biodefense pharmaceutical company. His work includes engagement with
Congress, federal agencies, and national security stakeholders supporting medical countermeasures within the U.S.
Strategic National Stockpile and broader biodefense infrastructure.
Earlier in his career, Kane advised senior political leaders and worked on major U.S. political campaigns, including
efforts supporting U.S. Senators and Members of Congress. His experience spans government relations, policy
strategy, and political advisory work across federal and state levels.
US Defense Areas of Interest
✓ Antimicrobials – MDR Bacteria and Biothreat Pathogens
✓ Burn and Blast Medical Countermeasures
✓ Combat Wound infections
✓ Biodefense – CBRN Threats
22
✓ Scalable, pathogen-agnostic approaches
✓ Rapid treatment for point-of-care battlefield use
✓ Commercial-scale production of antimicrobials
Broad Research Theme: seeking
unconventional approaches outside the
mainstream that challenge assumptions
and have the potential to radically change
established practice.
Key areas include war fighter health
countermeasures for biological threats,
and platform technologies that integrate.
Applications for the Warfighter
Proof-of concept
23
• Military personnel are vulnerable to the morbidity and mortality
associated with infections resulting from burn wounds sustained
during combat.
• Evacuation from the field to a treatment facility is often not timely
and wounds are typically contaminated with a multitude of
potent bacteria from soil and the surrounding environment.
• Immediate, on-the-field application of an effective topical
antimicrobial agent is needed to arrest microbial proliferation
and prevent downstream secondary sequelae from uncontrolled
infection.
• The cooling and protective properties of an antimicrobial agent
delivered within a hydrogel stands to aid pain relief and promote
wound healing.
• Antimicrobial resistance may be the most important infectious
disease threat of our time1 – HHS, CDC
The Challenge The Solution
• An acute intervention for military burn wounds sustained in a
combat setting
• Gel or Hydrogel could replace a suite of traditional topical
antibiotics for use in the field and be supplemented in the clinic by
systemic treatment where warranted
• Broad-spectrum platform
• Efficacious against MDR pathogens
• Rapid-acting
• Ability to be applied by non-medical professional
• Intravenous administration may be used in field hospital/military
bases
• Recce’s New Class of Synthetic Anti-Infectives have a unique
mechanism of action with the ability to overcome hyper-cellular
mutation of bacteria
1https://www.hhs.gov/about/agencies/oga/global-health-security/antimicrobial-resistance/index.html
Project: A Novel, Synthetic Anti-infective
Drug Candidate, R327, for the Acute
Treatment of Burn Wounds and
Downstream Sequelae
Goal: Develop room-temperature-stable,
sterile R327 amorphous hydrogel dressing
in sachets for field use; evaluate efficacy to
treat burn wound infections in animal
thermal wound infection models.
US Department of War Overview
2
CRADA with the U.S.
Army Medical Research
Institute of Infectious
Diseases
Project: Core Antibiotic Screening Program
Funded by DTRA. Testing R327 against a
panel of biothreat pathogens
Update: Preliminary testing with R327 is
ongoing with 30-strain panels of biodefense
pathogens including Burkholderia
pseudomallei and Yersinia pestis along with
control strains E. coli (ATCC 25922), S.
aureus (ATCC 29213) and P.
aeruginosa (ATCC27853).
U.S. Department of Defense
Congressionally Directed
Medical Research Program
(CDMRP)
CRADA with the U.S. Army
Institute of Surgical
Research (USAISR)
Project: To evaluate the efficacy of R327G in
reducing the bioburden of Pseudomonas
aeruginosa / Staphylococcus aureus in Burn
Wounds in the USAISR Walker-Mason rat
model.
RECCE® 327
Clinical
Programs
25
Pre-Clinical Programs
Michele Dilizia
Executive Director & Chief Scientific Officer
Contributors to Antibiotic Resistance
26
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC 6604941/
Most antimicrobial compounds are naturally-produced molecules, and, as such, co-resident bacteria have evolved
mechanisms to overcome their action in order to survive.
• Increased consumption of antimicrobial drugs
– Both by humans and animals; and improper prescribing of antimicrobial therapy.
• Overuse of many common antimicrobials agents by physicians
may occur
– The choice of drug is based on a combination of low cost and low toxicity.
• Improper prescribing of antimicrobials drugs
– Initial prescription of a broad-spectrum drug that is unnecessary or ultimately found
to be ineffective for the organism(s) causing the infection.
• Prior use of antimicrobial drugs
– Puts a patient at risk for infection with a drug-resistant organism, and those
patients with the highest exposure to antimicrobials are most often those who are
infected with resistant bacteria.
The emergence and
spread of drug-resistant
pathogens that have
acquired new resistance
mechanisms continues to
threaten the ability to
treat common infections.
4
27
VAP is a Common Infection that Typically Occurs in the ICU
MV: Mechanical Ventilator.
Source: Luo W. BMC Infectious Disease. 2021; Xi J. Clinical Infectious Diseases. 2018; El -Saed A. International Journal of Infectious
Diseases. 2013. UptoDate; ClearView Analysis.
• VAP typically occurs in the ICU, but may also present in other
settings where mechanical ventilation occurs
• Critical care specialists are typically the disease managers for
VAP patients
Typical Setting of Care
Primary route of infection is
micro-aspiration of organisms
in the throat, with ventilator
endotracheal tube facilitating
entrance of organisms to the
lungs
• VAP is considered a subset of HAP that develops after >48 hours
of mechanical ventilation and is a common issue in the ICU that
significantly increases patient risk of death
• High mortality associated with VAP given
comorbidities and drug resistance, with rates
ranging from 30 – 70%
Disease Burden
Morbidity
Low High
Mortality
• A 2021 study elucidated morbidity, as
patients with VAP had significantly longer
ICU stays, hospital length of stay, and
total time on ventilator compared to those
without VAP
• Increased time on mechanical ventilation
may also lead to long-term vocal cord
damage and increase risk of blood clots
Common Pathogens
P. Aeruginosa (20 – 30%)
Acinetobacter spp. (20 – 30%)
K. pneumoniae (5 – 10%)
E. Coli (<5%)
S. aureus (15 – 20%, ~30% of which is MRSA)
Increasing
Frequency
Gram
Negative
Gram
Positive
Gram
Negative
High clinical burden given comorbidities associated with hospitalised patients
Overview of Ventilator-associated Pneumonia (VAP)
Low High
Low High
28
Decreased Time
on Mechanical
Ventilation
Improved Methods
of Culturing and
Diagnosis
Superior First Line
Antibiotics for
MDR Pathogens
DEGREE OF NEED DESCRIPTION PHYSICIAN INSIGHT
Overall Unmet
Need
High unmet need in VAP is driven by significant morbidity and mortality
Source: Physician Interviews; ClearView Analysis.
Physician Perspectives on Key Unmet Needs in VAP
Key:
High Unmet
Need
Low Unmet
Need
• Physicians noted that time on mechanical ventilation
can lead to mortality and long-term morbidity (e.g.,
lung trauma, vocal cord damage), with even short
increases in duration resulting in extended need for care
“Prolonged time on MV can be a
burden for patients which may
lead to prolonged hospital care
and need for pulmonary rehab.”
• Delay time to initiation of targeted treatment given
delays for culture results, and oftentimes cultures do
not show any targetable pathogens
– Targeted treatment leads to higher likely efficacy
“If we could understand what
pathogens a patient has right
away, we could start by targeting
that.”
• Up to 60% of patients do not respond to first line
therapy, often given VAP is caused by MDR pathogens,
and delayed resolution can lead to worsening of initial
comorbidity and increase hospitalization and MV times
“Patients are often are not
responding to empiric treatments,
which just leaves time for their
condition to deteriorate.”
R327 may have potential to address key unmet needs within VAP by decreasing time on
mechanical ventilation (and thus morbidity and mortality), as well as demonstrating efficacy in
MDR pathogens
High
Low
Due to high prevalence of MDR pathogens
recce.com.au
R327 Demonstrates Potent Efficacy
Against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Lung Infection
Model: Hospital-Acquired Pneumonia (HAP) caused by Carbapenem-Resistant Acinetobacter baumannii (CRAB)
Design: 40 female mice assigned to 7 groups; treated with R327, placebo, saline, or meropenem via intranasal (IN) or nebulised (Neb) delivery.
Results at 24h post-infection:
Both IN and Neb R327 was well tolerated and
significantly reduced lung bacterial burden vs.
untreated and placebo groups.
Nebulised R327 resulted in a 4-log reduction
(>99.99%) lower bacterial burden in the lungs,
nearing the limit of detection (LoD), showing
strong local infection control.
Meropenem reduced bacterial load but is
restricted to IN use, limiting clinical practicality.
R327 Advantage: Unlike meropenem (not suitable
for nebulisation due to solubility limits), R327 can
be effectively nebulised, enabling direct lung
delivery.
Tuberculosis Burden in Indonesia
30
Tuberculosis is a highly serious and potentially fatal infectious disease that continues to pose a
major global health challenge.
• Tuberculosis continues to represent a major global unmet medical need, with ~10.8
million new cases annually worldwide.¹
• Indonesia accounts for ~10% of global TB cases, making it one of the largest
tuberculosis healthcare markets worldwide.⁴
• Tuberculosis causes around 14 deaths every hour in Indonesia, highlighting the
scale of the national disease burden.²
• The disease is estimated to cost ~US$6.9 billion annually in economic impact,
reflecting one of the largest infectious disease burdens globally.³
Source: (1) h ttp s :// ke m ke s.g o .i d /e n g /i n d on e si a s- m o ve m e nt -to - e n d- tb (2) https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-
tuberculosis-report-2024/featured-topics/the-second-national-tb-inventory-study-in-indonesia (3) (WHO / Stop TB Partnership) (4) World Health Organization. Global Tuberculosis Report 2024.
Mycobacterium fortuitum
• Objective: The aim of the study was to evaluate the efficacy of
R327A and R327B against Mycobacterium fortuitum
(ATCC6841TM) in the mouse intravenous infection model.
• Results: Both R327A and R327B showed dose dependent
antibacterial effect in Kidneys on days 8 and 10.
– R327A - Significant decrease in bacterial load was
observed with 50 and 100 mg/kg on days 8 and 10 Post
Infection (PI) (P<0.05) when compared to the corresponding
vehicle controls.
– R327B - Significant decrease in bacterial load was
observed with 100, 500 and 1000 mg/kg on days 8 and 10
PI (P<0.05) when compared to the corresponding vehicle
controls.
– Day 10 PI, R327B achieved a superior bacterial load
Share your feedback
Discover